

KENYA Support for Measles-Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

| | | |
|---|-------------|--------------------------|
| 1. Country: Kenya | | |
| 2. Grant number: 19-KEN-34a-X / 19-KEN-35a-Y | | |
| 3. Date of Decision Letter: 18 January 2019 | | |
| 4. Date of the Partnership Framework Agreement: 24 November 2014 | | |
| 5. Programme title: New Vaccine Support (NVS), Measles-Rubella Follow-up Campaign | | |
| 6. Vaccine type: Measles-Rubella | | |
| 7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED | | |
| 8. Programme duration¹: 2019 | | |
| 9. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable) | | |
| | 2019 | Total² |
| Programme Budget (US\$) | 4,979,500 | 4,979,500 |
| 10. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ³ | | |
| Type of supplies to be purchased with Gavi funds in each year (Campaign) | 2019 | |
| Number of Measles-Rubella vaccines dose | 7,648,400 | |
| Annual Amounts (US\$) | 4,979,500 | |
| 11. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF. | | |
| 12. Self-procurement: N/A | | |
| 13. Co-financing obligations for campaign: Reference code: 19-KEN-34a-X-C The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year. | | |
| Type of supplies to be purchased with Country funds in each year | 2019 | |
| Number of vaccine doses | 402,600 | |

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the amount that Gavi has approved.

| | | | | | | | | | |
|--|---|---------|--|--|------|--|--------------|---|-------------|
| | Number of AD syringes | | | | | | | | |
| | Number of re-constitution syringes | | | | | | | | |
| | Number of safety boxes | | | | | | | | |
| | Value of vaccine doses (US\$) | 257,629 | | | | | | | |
| | Total co-financing payments (US\$) (including freight) | 262,500 | | | | | | | |
| 14. Vaccine introduction grant (in US\$): N/A | | | | | | | | | |
| <p>15. Operational support for campaigns: The support for operational costs for campaign will be disbursed in cash through UNICEF. The Country will need to contact the local UNICEF office to arrange the utilisation of GAVI funds to support the operational costs of the campaign. Payable up to six months before campaign.</p> <table border="1"> <tr> <td></td> <td>2019</td> </tr> <tr> <td>Grant amount (US\$)</td> <td>3,989,173.65</td> </tr> </table> | | | | | 2019 | Grant amount (US\$) | 3,989,173.65 | | |
| | 2019 | | | | | | | | |
| Grant amount (US\$) | 3,989,173.65 | | | | | | | | |
| 16. Additional reporting requirements: | | | | | | | | | |
| In accordance with applicable Gavi processes, Kenya shall report on programmatic and financial performance. | To be agreed with Secretariat | | | | | | | | |
| To report on national and sub-national programmatic readiness using the WHO Readiness Assessment Tool (or equivalent) at the recommended time points | Starting 15 months prior to campaign date, up to 1 week before the campaign, at the recommended time points of the tool | | | | | | | | |
| To submit the Supplementary Immunisation Activity (SIA) technical report for Measles or Measles-Rubella campaign | Within 3 months of end of campaign | | | | | | | | |
| To submit the Post campaign coverage survey report for Measles or Measles-Rubella campaign | As soon as available | | | | | | | | |
| 17. Financial clarifications: Not applicable | | | | | | | | | |
| <p>18. Other conditions: As a condition to Gavi's support for measles and rubella, country will be required to fully self-finance with domestic resources the measles component of the first dose of measles containing vaccine (MCV1) in its national immunisation programme for 2018 and onwards.</p> <table border="1"> <tr> <td></td> <td>2019</td> </tr> <tr> <td>Minimum number of routine doses to be financed from domestic resources</td> <td>1,146,725</td> </tr> <tr> <td>Minimum amount to be co-financed from domestic resources (US\$)</td> <td>US\$733,904</td> </tr> </table> | | | | | 2019 | Minimum number of routine doses to be financed from domestic resources | 1,146,725 | Minimum amount to be co-financed from domestic resources (US\$) | US\$733,904 |
| | 2019 | | | | | | | | |
| Minimum number of routine doses to be financed from domestic resources | 1,146,725 | | | | | | | | |
| Minimum amount to be co-financed from domestic resources (US\$) | US\$733,904 | | | | | | | | |

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
18 January 2019